New drug indication approval - September 2024
For the most updated information related to registered therapeutic products, please refer to the Register of Therapeutic Products.
| Product Name | TRULICITY INJECTION 0.75MG/0.5ML,
TRULICITY INJECTION 1.5MG/0.5ML |
| Active Ingredient (Strength) | Dulaglutide(0.75mg/0.5ml),
Dulaglutide(1.5mg/0.5ml) |
| Product Registrant | DKSH SINGAPORE PTE. LTD. |
| Date of Approval | 12/09/2024 |
Indications:
Trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
∙ as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
∙ in addition to other medicinal products for the treatment of diabetes. |
| Product Name | TAGRISSO TABLET 40MG and 80MG |
| Active Ingredient (Strength) | Osimertinib (40mg, 80mg) |
| Product Registrant | Astrazeneca Singapore Pte Ltd |
| Date of Approval | 26/09/2024 |
Indications:
TAGRISSO (osimertinib) is indicated in combination with:
∙ pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.
*Evaluated as part of Project Orbis |
Healthcare professional, Industry member, Therapeutic Products
Published:
New Drug Indication Approvals